- H.C. Wainwright has lowered TG Therapeutics Inc's TGTX price target to $84 from $89 and keeps a Buy rating on the stock.
- Analyst Edward White mentioned that Ukoniq (umbralisib) revenue of $1.5 million was lower than expected in Q2. He believes gaining access to customers due to COVID-19 could remain a challenge into 2022.
- Ukoniq is indicated for relapsed or refractory marginal zone lymphoma who have received at least one prior anti-CD20 based regimen.
- The Company posted a wider than anticipated Q2 net loss of $(0.59) per share, well below the consensus loss $(0.50).
- Cash, cash equivalents, and investment securities were $456.2 million, which the Company believes will be sufficient to fund the Company's planned operations into 2023.
- Price Action: TGTX shares are down 19.9% at $28.10 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: Analyst ColorBiotechEarningsNewsShort IdeasHealth CarePrice TargetReiterationAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in